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OBJECTIVES The objective of this study was to examine the relationship between Chlamydia pneumoniae
seropositivity and aortic atherosclerotic plaques in the general population.
BACKGROUND Seroepidemiologic studies suggest that C pneumoniae infection plays a role in the pathogenesis
of atherosclerosis.
METHODS Transesophageal echocardiography was performed in 385 subjects (median age 66 years,
range 51 to 101 years; 53% men), a sample of the Olmsted County (Minnesota) population.
The association between C pneumoniae immunoglobulin (Ig) G antibody titers and aortic
atherosclerotic plaques was examined.
RESULTS Chlamydia pneumoniae IgG antibodies (titers 1:16) were detected in 287 subjects (74.5%):
low titers (1:16 to 1:32) in 58 (15.1%), intermediate titers (1:64 to 1:128) in 144 (37.4%), and
high titers (1:256) in 85 subjects (22.1%). Antibody titers were not associated with the
presence of aortic plaques after adjustment for age, gender, and smoking status (p  0.64).
Compared with titers 1:16, the adjusted odds ratios for aortic plaques were 1.46 (95%
confidence interval [CI] 0.63 to 3.42) for low titers, 1.32 (95% CI 0.68 to 2.55) for
intermediate titers, and 0.94 (95% CI 0.42 to 2.07) for high titers. Among the subgroup with
plaques, antibody titers were not associated with the presence of plaques 4 mm thick (p 
0.99), plaques 6 mm (p  0.49), or mobile debris (p  0.71), after adjustment for age and
smoking.
CONCLUSIONS Chlamydia pneumoniae IgG antibody titers are not associated with the presence or severity of
aortic atherosclerosis in the general population. These observations do not support a role for
C pneumoniae infection in the initiation or progression of atherosclerosis. (J Am Coll
Cardiol 2003;41:1482–7) © 2003 by the American College of Cardiology Foundation
Inflammation plays a central role in the pathogenesis of
atherosclerotic vascular disease and its atherothrombotic
complications (1). It has been postulated that chronic
infection with various pathogens may promote arterial
inflammation, thereby contributing to the initiation and/or
progression of atherosclerosis (2). Several large seroepide-
miologic studies have observed an association between
Chlamydia pneumoniae seropositivity and clinical coronary
artery disease (3–5) and cerebrovascular disease (6), suggest-
ing that chronic C pneumoniae may play a causal role in the
atherosclerotic process. However, these observations are
inconsistent with those of other studies (7–10). Thus, the
importance of C pneumoniae infection in the pathogenesis of
atherosclerotic vascular disease remains to be determined
(11).
The Stroke Prevention: Assessment of Risk in a Com-
munity (SPARC) study is a National Institutes of Health-
funded, population-based study designed to evaluate the
prevalence of risk factors for stroke in the general population
(12–14). Subjects were evaluated by transesophageal echo-
cardiography (TEE), thereby allowing determination of the
frequency and severity of aortic atherosclerosis in the pop-
ulation. The objective of the current study was to examine
the relationship between seropositivity for C pneumoniae
and anatomically defined atherosclerosis (aortic atheroscle-
rotic plaques identified on TEE) in a sample of the general
population, in an attempt to clarify the role of C pneumoniae
infection in atherogenesis.
METHODS
Study population. The study design and results of phase I
of the SPARC study have been published recently in detail
(12,13). The original study cohort consisted of 581 subjects,
a random sample of Olmsted County (Minnesota) residents
45 years old, stratified by age and gender. Approximately
four to five years (median 4.6 years, range 3.8 to 5.4 years)
after their initial evaluation, eligible subjects were enrolled
in phase II of the study. Of 504 subjects eligible for phase II
(excluding 3 subjects from the original cohort lost to
follow-up, 54 deceased, and 20 with severe medical disabil-
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ities precluding participation), 392 (78%) agreed to partic-
ipate (14). Transesophageal echocardiography was repeated
successfully in 388 subjects (99% of phase II participants),
385 of whom were included in the current analysis (two
subjects were excluded because of incomplete echocardio-
graphic data, and one subject was excluded because of
positive immunoglobulin [Ig] M antibodies [titer 1:10]
indicating acute C pneumoniae infection). The median age
of the study population was 66 years (range 51 to 101 years);
53% were men. The study was approved by the Mayo
Foundation Institutional Review Board. Written informed
consent was obtained from all subjects.
Clinical and laboratory data. Smoking status (current
smoker, past smoker, or never smoked) was elicited by
questionnaire. Previous clinical coronary artery disease and
cerebrovascular disease were ascertained by questionnaire
and abstracting of medical records at Mayo Clinic and
Olmsted Medical Center, the two primary health care
providers in Olmsted County.
Fasting blood samples were collected (on the day of TEE
in 97% of subjects and within 20 days of TEE in the
remaining subjects) and, using commercially available as-
says, were analyzed for the following infectious and inflam-
matory markers:
1) Chlamydia pneumoniae (TW 183) IgG and IgM anti-
body titers, with use of a microimmunofluorescence
assay (MRL, Focus Technologies, Cypress, California).
Seropositivity was defined as an IgG titer of 1:16 (7).
Among seropositive subjects, antibody titers were de-
fined as low (1:16 to 1:32), intermediate (1:64 to 1:128),
or high (1:256).
2) Blood counts, including white blood cell differential
counts.
3) Fibrinogen levels.
4) High-sensitivity C-reactive protein (hs-CRP) levels,
with use of a high-sensitivity, latex-enhanced, immuno-
tubidimetric assay (Kamiya Biomedical, Seattle,
Washington).
TEE. Transesophageal echocardiography was performed
using commercially available ultrasound instruments
equipped with multiplane probes (Sequoia Ultrasound Sys-
tem, Acuson, Mountain View, California). The three seg-
ments of the thoracic aorta (ascending aorta, aortic arch, and
descending thoracic aorta) were imaged in short- and
long-axis views using high-frequency (7-MHz) ultrasono-
graphic imaging. Atherosclerotic plaques were defined as
irregular intimal thickening (at least 2 mm thick). The
presence of plaques in the thoracic aorta (plaques of any
degree in any aortic segment) was determined. Among
subjects with plaques, the maximal plaque thickness and the
presence of mobile aortic debris (in any segment of the
aorta) were determined. For this analysis, plaque thickness
was dichotomized arbitrarily at 4 mm (15) and 6 mm
(detected in approximately 10% of the study population).
Statistical analysis. Continuous data are summarized as
medians and interquartile ranges (25% to 75%); categorical
data are summarized as percentages. For continuous data,
groups were analyzed using the Kruskal-Wallis nonpara-
metric test. For categorical data, groups were analyzed using
the chi-square statistic or Fisher exact test (when the
expected number of subjects in a cell, under the null
hypothesis, was 5).
Logistic regression was used to determine the relation-
ship between C pneumoniae antibody titers and the odds of
having aortic plaques (proportion of subjects with plaques of
any degree divided by proportion without plaques). Among
subjects with plaques, the odds of having plaques 4 mm
thick (proportion with plaques 4 mm divided by propor-
tion with plaques 4 mm), plaques 6 mm thick (propor-
tion with plaques 6 mm divided by proportion with
plaques 6 mm), and mobile debris (proportion with
plaques with mobile debris divided by proportion with
plaques without debris) were determined.
Univariate (unadjusted) odds ratios (ORs) and their 95%
confidence intervals (CIs) were estimated. Subsequently,
ORs were estimated after adjustment for age, gender (for
selected plaque variables), and smoking status (7,16) (7.0%
of study participants were current smokers, 38.4% were past
smokers, and 54.6% never smoked). Odds ratios were
adjusted for gender for plaque variables with a large number
of subjects (plaques of any degree and plaques 4 mm).
Smoking was modeled as current smoker and past smoker
(vs. never smoked) for plaque variables with a large number
of subjects or as ever smoked (vs. never smoked) for plaque
variables with a small number of subjects (plaques 6 mm
and mobile debris).
RESULTS
Aortic plaques (of any degree) were detected in 266 subjects
(69.1% of subjects). Plaques were uncommon in the ascend-
ing aorta (23 subjects, 6.0%) but were common in the aortic
arch (243 subjects, 63.1%) and descending thoracic aorta
(210 subjects, 54.5%). Plaques 4 mm, plaques 6 mm,
and plaques with mobile debris (in any segment of the aorta)
were detected in 113, 41, and 20 subjects, respectively.
Two hundred eighty-seven subjects (74.5%) were C
pneumoniae seropositive (IgG titers 1:16). Low titers were
present in 58 subjects (15.1%), intermediate titers in 144
subjects (37.4%), and high titers in 85 subjects (22.1%).
Table 1 presents the distribution of C pneumoniae antibody
Abbreviations and Acronyms
CI  confidence interval
hs-CRP  high-sensitivity C-reactive protein
Ig  immunoglobulin
OR  odds ratio
SPARC  Stroke Prevention: Assessment of Risk
in a Community
TEE  transesophageal echocardiography
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titers in relation to the presence or absence of specific plaque
variables. There was no significant difference in the distri-
bution of C pneumoniae titers between subjects with and
those without aortic plaques (of any degree). Among sub-
jects with plaques, there were no significant differences in
the distribution of C pneumoniae titers according to the
presence or absence of severe plaque characteristics (plaques
4 mm, plaques 6 mm, and mobile debris).
The ORs for aortic plaques in relation to C pneumoniae
antibody titers are summarized in Table 2. Chlamydia
pneumoniae titers were not associated with the presence of
aortic plaques (of any degree), either univariately or after
adjustment for age, gender, and smoking status. Among
subjects with plaques, high titer was apparently associated
with the presence of plaques 4 mm by univariate analysis
(OR 2.05, compared with titers 1:16; 95% CI 1.00 to
4.21), but this association was not significant after adjust-
ment for age, gender, and smoking status (adjusted OR 1.11;
95% CI 0.47 to 2.60). Moreover, the joint inclusion of all three
levels of C pneumoniae antibody titers was not a significant
addition to the unadjusted model (p  0.20) or to the age-,
gender-, and smoking-adjusted model (p  0.99) of plaques
4 mm. Chlamydia pneumoniae titers were not associated with
plaques 6 mm or with mobile debris, either univariately or
after adjustment for age and smoking status.
The associations between C pneumoniae antibody titers
and all plaque variables remained nonsignificant after ad-
justment for additional aortic atherosclerotic risk factors
(data not shown). Furthermore, the association between
C pneumoniae titers and severe plaque features remained
Table 1. Distribution of Chlamydia pneumoniae Immunoglobin Antibody Titers in Relation to the Presence and Severity of Aortic
Atherosclerotic Plaques
Plaque Variables
Antibody Titer
p Value*
Negative
(<1:16)
n  98
Low
(1:16–1:32)
n  58
Intermediate
(1:64–1:128)
n  144
High
(>1:256)
n  85
Aortic plaques (any degree)
Present (n  266) 63 (23.7) 42 (15.8) 100 (37.6) 61 (22.9) 0.65
Absent (n  119) 35 (29.4) 16 (13.4) 44 (37.0) 24 (20.2)
Plaques 4 mm†
Present (n  113) 23 (20.4) 17 (15.0) 40 (35.4) 33 (29.2) 0.20
Absent (n  153) 40 (26.1) 25 (16.3) 60 (39.2) 28 (18.3)
Plaques 6 mm†
Present (n  41) 10 (24.4) 7 (17.1) 16 (39.0) 8 (19.5) 0.95
Absent (n  225) 53 (23.6) 35 (15.6) 84 (37.3) 53 (23.6)
Mobile debris†
Present (n  20) 5 (25.0) 2 (10.0) 9 (45.0) 4 (20.0) 0.89‡
Absent (n  246) 58 (23.6) 40 (16.3) 91 (37.0) 57 (23.2)
Data presented are numbers of subjects (percentages of subjects with or without the specific plaque variable in parentheses). *Comparison of subjects with and without the specific
plaque variable. Groups were compared using the chi-square statistic, unless otherwise indicated. †Analysis confined to subgroup of 266 subjects with aortic plaques (of any
degree). ‡Groups were compared using the Fisher exact test.
Table 2. Association of Chlamydia pneumoniae IgG Antibody Titers With the Presence and Severity of Aortic Atherosclerotic Plaques
Unadjusted OR Adjusted OR*
OR 95% CI p Values† OR 95% CI p Values†
Aortic plaques (any degree)
Low titer (1:16–1:32) 1.46 0.72–2.96 0.30 1.46 0.63–3.42 0.38
Intermediate titer (1:64–1:128) 1.26 0.73–2.18 0.40 0.66 1.32 0.68–2.55 0.41 0.64
High titer (1:256) 1.41 0.75–2.65 0.28 0.94 0.42–2.07 0.87
Plaques 4 mm‡
Low titer (1:16–1:32) 1.18 0.53–2.64 0.68 1.04 0.42–2.60 0.93
Intermediate titer (1:64–1:128) 1.16 0.61–2.22 0.66 0.20 0.97 0.45–2.09 0.94 0.99
High titer (1:256) 2.05 1.00–4.21 0.05 1.11 0.47–2.60 0.82
Plaques 6 mm‡
Low titer (1:16–1:32) 1.06 0.37–3.05 0.91 0.97 0.32–2.98 0.96
Intermediate titer (1:64–1:128) 1.01 0.43–2.39 0.98 0.96 0.97 0.38–2.44 0.95 0.49
High titer (1:256) 0.80 0.29–2.19 0.66 0.50 0.17–1.48 0.21
Mobile debris‡
Low titer (1:16–1:32) 0.58 0.11–3.14 0.53 0.54 0.10–2.96 0.48
Intermediate titer (1:64–1:128) 1.15 0.37–3.59 0.81 0.83 1.10 0.34–3.51 0.88 0.71
High titer (1:256) 0.81 0.21–3.19 0.77 0.61 0.15–2.51 0.49
Data presented as OR for each titer level relative to negative titer (1:16). *OR adjusted for age, gender, current smoking, and past smoking (aortic plaques of any degree, plaques
4 mm) and adjusted for age and ever smoking (plaques 6 mm, mobile debris). †p values presented for each titer category separately (left columns) and for joint inclusion of
all titer categories (right columns). ‡Analysis confined to subgroup of subjects with aortic plaques (of any degree).
CI  confidence interval; Ig  immunoglobulin; OR  odds ratio.
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nonsignificant in an additional post hoc analysis, in which
subjects with severe plaque characteristics were compared
with the rest of the study population (i.e., compared with
subjects with plaques of lesser severity or without plaques;
data not shown).
The distribution of C pneumoniae antibody titers was not
significantly different between subjects with and those
without clinical coronary artery disease and cerebrovascular
disease (Table 3). Blood cell counts (including white blood
cell differential counts), fibrinogen levels, and hs-CRP levels
were not significantly different among subjects with various
C pneumoniae titers (Table 4).
Table 3. Distribution of Chlamydia pneumoniae IgG Antibody Titers in Relation to Frequency of Clinical Coronary Artery Disease
and Cerebrovascular Disease
Clinical Variable
Antibody Titer
p Value*
Negative
(<1:16)
n  98
Low
(1:16–1:32)
n  58
Intermediate
(1:64–1:128)
n  144
High
(>1:256)
n  85
Coronary artery disease†
Present (n  68) 14 (20.6) 9 (13.2) 26 (38.2) 19 (27.9) 0.52
Absent (n  317) 84 (26.5) 49 (15.5) 118 (37.2) 66 (20.8)
Myocardial infarction
Yes (n  36) 7 (19.4) 5 (13.9) 16 (44.4) 8 (22.2) 0.77
No (n  349) 91 (26.1) 53 (15.2) 128 (36.7) 77 (22.1)
Angina pectoris
Yes (n  58) 11 (19.0) 9 (15.5) 23 (39.7) 15 (25.9) 0.64
No (n  327) 87 (26.6) 49 (15.0) 121 (37.0) 70 (21.4)
CABG
Yes (n  21) 3 (14.3) 4 (19.0) 8 (38.1) 6 (28.6) 0.59‡
No (n  364) 95 (26.1) 54 (14.8) 136 (37.4) 79 (21.7)
PTCA
Yes (n  14) 4 (28.6) 0 (0.0) 8 (57.1) 2 (14.3) 0.27‡
No (n  371) 94 (25.3) 58 (15.6) 136 (36.7) 83 (22.4)
Cerebrovascular disease§
Present (n  33) 8 (24.2) 6 (18.2) 14 (42.4) 5 (15.2) 0.73
Absent (n  352) 90 (25.6) 52 (14.8) 130 (36.9) 80 (22.7)
Ischemic stroke
Yes (n  14) 2 (14.3) 2 (14.3) 8 (57.1) 2 (14.3) 0.52‡
No (n  371) 96 (25.9) 56 (15.1) 136 (36.7) 83 (22.4)
TIA
Yes (n  21) 6 (28.6) 3 (14.3) 9 (42.9) 3 (14.3) 0.85‡
No (n  364) 92 (25.3) 55 (15.1) 135 (37.1) 82 (22.5)
Carotid endarterectomy
Yes (n  4) 0 (0.0) 2 (50.0) 2 (50.0) 0 (0.0) 0.14‡
No (n  381) 98 (25.7) 56 (14.7) 142 (37.3) 85 (22.3)
Data presented are numbers of subjects (percentages of subjects with or without the specific clinical variable in parentheses). *Comparison of subjects with and without the specific
clinical variable. Groups were compared using the chi-square statistic, unless otherwise indicated. †Coronary artery disease defined as the presence of any of the following:
myocardial infarction, angina pectoris, CABG, or PTCA. ‡Groups were compared using the Fisher exact test. §Cerebrovascular disease defined as the presence of any of the
following: ischemic stroke, TIA, or carotid endarterectomy.
CABG  coronary artery bypass grafting; Ig  immunoglobulin; PTCA  percutaneous transluminal coronary angioplasty; TIA  transient ischemic attack.
Table 4. Blood Cell Counts, Fibrinogen, and hs-CRP in Relation to Chlamydia pneumoniae Antibody Titer
Variable
Antibody Titer
p Value
Negative
(<1:16)
Low
(1:16–1:32)
Intermediate
(1:64–1:128)
High
(>1:256)
Blood cell counts
Hematocrit, % 40.2 (38.4–42.9) 41.0 (38.6–42.7) 41.4 (38.6–43.3) 41.4 (39.2–43.5) 0.24
Leukocytes,  109/l 5.6 (4.8–6.4) 5.1 (4.6–6.1) 5.6 (4.8–6.5) 5.6 (4.8–6.4) 0.21
Neutrophils,  109/l 3.1 (2.7–3.8) 3.1 (2.3–3.9) 3.3 (2.7–3.9) 3.4 (2.6–3.9) 0.39
Lymphocytes,  109/l 1.6 (1.3–2.1) 1.5 (1.2–1.7) 1.6 (1.3–2.0) 1.6 (1.3–1.9) 0.14
Monocytes,  109/l 0.47 (0.38–0.58) 0.44 (0.39–0.53) 0.49 (0.41–0.59) 0.50 (0.40–0.61) 0.10
Platelets,  109/l 211 (196–243) 200 (175–244) 207 (168–234) 206 (169–239) 0.35
Fibrinogen, mg/dl 384 (337–441) 381 (353–429) 406 (346–459) 388 (334–461) 0.52
hs-CRP, mg/dl 0.23 (0.11–0.53) 0.24 (0.12–0.45) 0.24 (0.11–0.45) 0.25 (0.11–0.52) 0.97
Data are median values (interquartile ranges in parentheses).
hs-CRP  high-sensitivity C-reactive protein.
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DISCUSSION
This population-based TEE study shows that C pneumoniae
seropositivity is not associated with the presence of aortic
atherosclerotic plaques. Among subjects with plaques, C
pneumoniae seropositivity is not associated with plaque
severity, as defined by maximal plaque thickness or the
presence of mobile debris. The lack of association between
C pneumoniae seropositivity and clinical coronary artery
disease or cerebrovascular disease in our study population
supports our echocardiographic-anatomic observations.
C pneumoniae and atherosclerotic plaques. Chlamydia
pneumoniae, a common respiratory pathogen, is frequently
detected in pathologic specimens of atherosclerotic plaques
(17–21), but its presence in plaques is related inconsistently
with plaque extent and severity (19,20,22,23). Using various
imaging techniques, the relationship between C pneumoniae
seropositivity and atherosclerosis has been examined in
highly selected patients undergoing invasive angiographic
studies (24,25) and in selected (26–28) and relatively
nonselected (29–31) populations undergoing noninvasive
ultrasonographic vascular imaging. Many of these studies
have found positive associations (24,28,29,31), and two
prospective studies have also shown an association between
C pneumoniae seropositivity and the progression of carotid
atherosclerosis (28,31). Nevertheless, these associations
were not borne out in a large study of healthy individuals
(30) or in our current study.
Notably, carotid artery intima-medial thickness, the main
measurement used in most ultrasonographic studies, is
representative of the early stages of atherogenesis. By
contrast, high-resolution, real-time TEE imaging allows
visualization of the full range of aortic atherosclerotic
plaques, from simple plaques to thick (“protruding”) plaques
(15) and mobile atherosclerotic debris, the echocardio-
graphic hallmark of ruptured aortic plaque with superim-
posed thrombosis (32). Using TEE, we were able to
examine the association between C pneumoniae seropositiv-
ity and both the presence and complexity of aortic plaques in
a large sample of the general population and to conclude
that previous (presumably chronic) infection with C pneu-
moniae, assessed serologically, does not appear to be in-
volved in the atherosclerotic process in either its early or its
more advanced stages.
An independent association between hs-CRP and aortic
plaques has been demonstrated recently in the SPARC
study population (33), an observation further supporting the
systemic inflammatory nature of the atherosclerotic process
(1). In our current analysis, C pneumoniae seropositivity was
not associated with various markers of systemic inflamma-
tion. This observation, also made by other investigators
(7,30), is consistent with the lack of association between C
pneumoniae seropositivity and aortic atherosclerosis in our
study population.
Study strengths and limitations. The SPARC study is the
only large-scale, population-based TEE study performed to
date. Study participants were sampled from the adult
population residing in a well-defined geographic area, are
relatively free of selection bias, and are representative of the
general population.
The following study limitations should be noted. First,
this was a cross-sectional study, one lacking prospective
follow-up data. However, data relating aortic plaque mor-
phology, C pneumoniae serology, and inflammatory markers
to future cardiovascular and cerebrovascular events will be
available during long-term follow up of the study cohort.
Second, we examined the association between C pneu-
moniae IgG antibody titers and aortic atherosclerosis, as-
suming that the presence of IgG titers beyond a certain
threshold (i.e., titers 1:16) is indicative of chronic C
pneumoniae infection (7). Moreover, we examined the asso-
ciation between various levels of antibody titers and aortic
atherosclerosis (4,7) and excluded one subject with positive
C pneumoniae IgM antibodies, assuming that higher IgG
titers are more likely to represent persistent C pneumoniae
infection (in the absence of acute infection). Nevertheless,
although widely studied (9) and widely available in clinical
practice, C pneumoniae IgG antibody titers may not be the
best serologic markers for assessing persistent infection, as
suggested by the weak association between seropositivity
and direct detection of C pneumoniae in atherosclerotic
plaques (18,20,23) and by the apparently stronger relation-
ship of C pneumoniae IgA titers (3,6,34,35), C pneumoniae
immune complexes (3,34), and circulating C pneumoniae
deoxyribonucleic acid (36) to atherosclerotic vascular dis-
ease.
Third, although we did not demonstrate any significant
association between C pneumoniae seropositivity and aortic
plaques, it is possible that the sample size of our study was
underpowered for detecting minor associations. However,
as shown in Table 2, the adjusted ORs for aortic plaques
were close to 1.0 (many of them were 1.0), and there was
no trend for increasing ORs with increasing titers (some
ORs for higher titers were even lower than for lower titers).
These findings suggest that a significant association be-
tween C pneumoniae seropositivity and aortic plaques is very
unlikely and, if an association does exist, it is minor and of
questionable clinical significance.
Finally, it has been postulated recently that the overall
burden of pathogens (i.e., the effect of the combined
presence of several infectious pathogens), not a specific
pathogen, is the important factor in the development of
atherosclerosis (37). Chlamydia pneumoniae was the only
infectious agent examined in our study; therefore, we cannot
reject the possibility that persistent C pneumoniae infection,
in conjunction with other infectious pathogens, promotes
the development of atherosclerosis.
Conclusions. Seropositivity for C pneumoniae is not related
to the presence or severity of aortic atherosclerotic plaques
in the general population. These echocardiographic-
anatomical findings do not support the hypothesis that
C pneumoniae infection plays a role in the pathogenesis of
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atherosclerotic vascular disease. In acknowledgment of the
potential limitations of seroepidemiologic assessment noted
above, the negative results of our study and other studies
(7–10) advocate that future studies should focus on nonse-
rologic methods to address the possible role of C pneumoniae
in atherogenesis.
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